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Abstract
Purpose
To evaluate the risk factors associated with loco-regional failure after surgical resection and
to identify the subgroup that can obtain benefits from adjuvant radiotherapy (RT).
Materials and Methods
We identified patients treated with surgical resection for resectable pancreatic cancer at
Severance hospital between January 1993 and December 2014. Patients who received
any neoadjuvant or adjuvant RT were excluded. A total of 175 patients were included. Adju-
vant chemotherapy was performed in 107 patients with either a gemcitabine-based regimen
(65.4%) or 5-FU based one (34.9%).
Results
The median loco-regional failure-free survival (LRFFS) and overall survival (OS) were 23.9
and 33.6 months, respectively. A recurrence developed in 108 of 175 patients (61.7%). The
predominant pattern of the first failure was distant (42.4%) and 47 patients (26.9%) devel-
oped local failure as the first site of recurrence. Multivariate analysis identified initial CA 19–
9 200 U/mL, N1 stage, perineural invasion (PNI), and resection margin as significant inde-
pendent risk factors for LRFFS. Patients were divided into four groups according to the
number of risk factors, including initial CA 19–9, N stage, and PNI. Patients exhibiting two
risk factors had 3.2-fold higher loco-regional failure (P < 0.001) and patients with all risk fac-
tors showed a 6.5-fold increase (P < 0.001) compared with those with no risk factors. In the
analysis for OS, patients with more than two risk factors also had 3.3- to 6-fold higher risk of
death with statistical significance.
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Conclusion
The results suggest that patients who exhibit more than two risk factors have a higher risk of
locoregional failure and death. This subgroup could be benefited by the effective local adju-
vant treatment.
Introduction
Pancreatic cancer is a fatal malignant disease and the fifth leading cause of cancer death in Korea.
[1] Surgical resection is thought to be the only curative treatment option for localized pancreatic
cancer, but only 10–15% of pancreatic cancer patients are resectable at presentation. Even the
median survival is only 10–18 months after surgery alone.[2–5] Most treatment failures occur
within 1–2 years after surgery in local recurrence, hepatic metastases, or both.[6,7] Systemic and
local adjuvant treatment have been investigated to define their effects. In the Gastrointestinal
Tumor Study Group (GITSG) trial,[8,9] median survival for the adjuvant chemoradiotherapy
(CRT) group was significantly longer than that observed for the control group (20 months vs. 11
months). However, the European Organization for Research and Treatment of Cancer (EORTC)
40891 trial did not show a statistically significant difference in progression-free survival (PFS) and
overall survival (OS) between two arms.[10,11] To clarify the effect of adjuvant CRT, the Euro-
pean Study Group for Pancreatic Cancer (ESPAC-1) trial was performed. Results from the
ESPAC-1 trial suggested that adjuvant CRT has a detrimental effect on survival compared with
surgery alone.[12,13] Conclusions drawn from the ESPAC-1 trial have raised questions about the
efficacy of adjuvant CRT for locally advanced pancreatic cancer, and consequently, current clinical
practices tend to exclude adjuvant radiotherapy (RT) from routine adjuvant treatment modalities.
In the clinical setting, however, loco-regional failures as the first recurrence are frequent,
resulting in an additional course of RT as a salvage treatment. While consensus regarding the
benefit of adjuvant RT is lacking, this study was designed to evaluate the risk factors associated
with loco-regional failure after surgical resection and to identify the subgroup of patients who
can benefit most from adjuvant RT.
Materials and Methods
Study population
We searched to identify all patients treated with surgical resection for pancreatic cancer at Severance
hospital from 1993 to 2014. A total of 411 patients were identified and retrospectively reviewed.
Among these patients, 236 were excluded from this analysis due to the following reasons: (1) receipt
of neoadjuvant CRT before surgical resection. (n = 78); (2) receipt of surgical resection as a palliative
aim for stage IV disease (n = 24); (3) receipt of postoperative CRT or RT (n = 39); (4) diagnosed
with neuroendocrine tumor (n = 60), intraductal papillary neoplasm (IPMN) without invasiveness
(n = 9), and solid pseudopapillary tumor (n = 10); (5) exhibited history of another primary cancer
(n = 5); and (6) follow-up after surgical resection was not performed (n = 11). Ultimately, a total of
175 patients were included for this analysis. This study was approved by Institutional review board
(IRB) of Yonsei University Health System. The patient records/information was anonymized and
de-identified prior to analysis, and informed consent was not obtained from each participants.
Preoperative assessment and treatment
Pretreatment evaluation included a review of previous medical history, physical examination,
laboratory tests and performance status. For staging workup, preoperative computerized
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tomography, magnetic resonance image, and 18F-fluorodeoxyglucose positron emission
tomography-CT were performed.
Resectability was assessed based on imaging studies according to the National Comprehensive
Cancer Network (NCCN) classification.[14] Resectable pancreatic cancer was defined as: (1) the
absence of distant metastasis, (2) no evidence of tumor invasion to the SMA or celiac axis, and (3)
none or less than 180 degree contact with superior mesenteric vein (SMV) or portal vein (PV) with-
out contour irregularity. Vascular invasion was defined as tumor-to-vessel circumferential contigu-
ity, either abutment ( 50% of the circumference) or encasement (> 50% of the circumference).
Surgical procedures were composed of pylorus-preserving pancreaticoduodenectomy
(PPPD), Whipple operation, or total pancreatectomy for pancreatic head cancer and partial pan-
createctomy for a pancreatic body and tail cancer. Surgical margins such as the pancreatic duct,
bile duct, retroperitoneal margin, duodenum, or stomach were evaluated grossly and microscopi-
cally to elucidate the status of the surgical margins. These surgical margins, with the exception of
the retroperitoneal margin, were often evaluated using frozen-section analysis, and if positive,
additional resection was performed. The final margin status was reported in the permanent
pathology report. Resection status was defined as complete resection with microscopically nega-
tive margins (R0), grossly complete resection with microscopically positive margins (R1), and
grossly incomplete resection (R2), which is determined by surgeons or on the postoperative
imaging studies. Adjuvant chemotherapy was performed in 107 patients (61.1%) with either a
gemcitabine-based regimen (70 patients, 65.4%) or 5-FU-based one (37 patients, 34.6%).
The following variables were collected for each patient: patient demographics (age, sex, dia-
betes mellitus (DM), Eastern Cooperative Oncology Group (ECOG) performance status),
tumor characteristics (size, stage, tumor marker, grade, lymphovascular invasion (LVI), peri-
neural invasion (PNI), lymph node (LN) metastasis, perinodal extension (PNE)), and patho-
logic margin status.
Statistical analysis
Study endpoints were loco-regional failure-free survival (LRFFS) and OS. Survival duration
was calculated from the date of surgical resection to the corresponding event (loco-regional
failure, distant metastasis, or death). We performed Pearson’s chi-squared test or Fisher’s exact
test to compare categorical variables. The area under the receiver-operating characteristic
(ROC) curve (AUC) was used to find optimal cut off value for preoperative CA 19–9 level. The
Kaplan–Meier method with log-rank test was used to analyze survival outcomes. Stepwise Cox
proportional hazards regression was used to perform a multivariable analysis on prognostic
factors for LRFFS and OS (inclusion criteria P< 0.05). All statistical tests were two-sided with
significance defined as P< 0.05. The data were analyzed using IBM SPSS software version 20.0
(SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics
A total of 175 patients were included in this study. The patient characteristics are summarized
in Table 1. The median age was 65 years (range, 34–84 years). ECOG performance status was 0
in 96 patients (54.9%) or 1 in 79 patients (45.1%). Among 122 pancreatic head cancer patients,
101 (58%) received PPPD, 19 (11%) received Whipple’s operation, and 2 (1%) received total
pancreatectomy. Fifty-three patients with pancreatic body or tail cancer received partial pan-
createctomy. Most of the patients were diagnosed with ductal adenocarcinoma (144 patients),
while mucinous carcinoma, acinar cell carcinoma, and IPMN with invasion were diagnosed in
6, 4, and 21 patients, respectively. One-hundred forty three patients were diagnosed with T3
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Table 1. Patient characteristics.
Characteristics n %
Age, mean (range), yr 63.3 (34–84)
Sex
Male 108 61.7
Female 67 38.3
ECOG performance status
0 96 54.9
1 79 45.1
Tumor location
Head 122 69.7
Body 36 20.6
Tail 17 9.7
Operation name
PPPD 101 57.7
Whipple operation 19 10.9
Total pancreatectomy 2 1.1
Partial pancreatectomy 53 30.3
Pathology
Ductal adenoca 144 82.3
Mucinous adenoca 6 3.4
Acinar cell ca 4 2.3
IPMN c invasiveness 21 12.0
T stage
T1 11 6.3
T2 14 8.0
T3 143 81.7
T4 7 4.0
N stage
N0 88 50.3
N1 87 49.7
Stage
I 21 12.0
IIA 67 38.3
IIB 81 46.3
III 6 3.4
Grade
WD 19 10.9
MD 108 61.7
PD-UD 15 8.5
Unknown 33 18.9
Tumor size
< 3cm 102 58.3
 3cm 73 41.7
LVI
No 121 69.1
Yes 54 30.9
PNI
No 66 37.7
(Continued)
Risk Factors Associated with LRF in RPC
PLOSONE | DOI:10.1371/journal.pone.0157196 June 22, 2016 4 / 12
stage based on their pathologic reports. Seven patients were diagnosed with T4 stage, which
was initially considered as resectable disease in the preoperative imaging studies. Eighty-seven
patients (49.7%) presented with positive nodal status. Resection status was R0 in 160 patients
and R1 in 15 patients. The preoperative and postoperative CA 19–9 level ranged from 0.1 to
20,000 U/mL, with a median of 90.3 U/mL and 0.1 to 2060 U/mL, with a median of 12.9 U/mL,
respectively. The AUC was 0.588 (95% Confidence interval (CI) 0.504–0.672, P = 0.046) for
preoperative CA 19–9 level and 0.541 (95% CI 0.454–0.627, P = 0.362) for postoperative CA
19–9 level. Patients were divided by the cutoff value of 200 U/mL for preoperative CA 19–9
and 40 U/mL for postoperative CA 19–9.
Survival outcomes and patterns of failure
With a median follow-up period of 21 months (range 4.0–109.2 months), 108 out of 175 patients
(61.7%) developed a recurrence. Median time to first failure was 14months. The cumulative actuar-
ial rates of any recurrence at 12 and 18 months were 41.6% and 56.5%, respectively. The median
LRFFS was 23.9 months and the median OS was 33.6 months with a 5-yr survival rate of 41.5%.
The patterns of failure are summarized in Table 2. Initial sites of failure were composed of
local failures (26.9%), regional failures (5.7%), and distant metastasis (42.4%), when counting
recurrences in the multiple sites separately. The predominant pattern of the first failure was
distant metastasis, mainly in the liver (n = 50), peritoneum (n = 14), lung (n = 10), paraaortic
lymph node (n = 3), and bone (n = 2). Among those who had a distant failure, 52 patients expe-
rienced distant failure only. Loco-regional failure without distant metastasis as a first site of
recurrence developed in 31 patients (17.7%).
Risk factors related to LRRF and OS
We analyzed the prognostic factors related to LRFFS and OS (Table 3). In the univariate analy-
sis, ECOG performance status, preoperative CA 19–9 ( 200 U/mL), postoperative CA 19–9
Table 1. (Continued)
Characteristics n %
Yes 109 62.3
Resection status
R0 160 91.4
R1 15 8.6
PNE
No 149 85.1
Yes 26 14.9
Preoperative CA 19–9
 200 U/mL 111 63.4
< 200 U/mL 64 36.6
Postoperative CA 19–9
 40 U/mL 130 74.2
< 40 U/mL 40 22.9
Unknown 5 2.9
Abbreviations: ECOG = Eastern Cooperative Oncology Group; PPPD = pylorus preserving
pancreaticoduodenectomy; IPMN = Intraductal papillary mucinous neoplasm; WD = well-differentiated;
MD = moderately-differentiated; PD = poorly-differentiated; UD = undifferentiated LVI = lymphovascular
invasion; PNI = perineural invasion; RM = resection margin; PNE = perinodal extension.
doi:10.1371/journal.pone.0157196.t001
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( 40 U/mL), N stage, AJCC stage, LVI, PNI, resection margin, and PNE were associated with
LRFFS with statistical significance. Among these, preoperative CA 19–9, N stage, PNI, and
resection margin were analyzed as independent prognostic factors for LRFFS in multivariate
analysis (Fig 1). Then, all patients were divided into four groups according to the number of
risk factors they possessed among these three factors: preoperative CA 19–9 ( 200 U/mL), N
stage, and PNI. Because positive resection margin is already known as a prognostic factor that
requires adjuvant RT, resection margin was not counted as a risk factor in the following analy-
sis. Group 0 was defined as patients who did not exhibit any risk factors, group 1 was defined
as those who had one risk factor, and group 2 was defined as those who possessed two risk fac-
tors. Group 3 was defined as patients who displayed all three risk factors.
LRFFS showed statistically significant differences according to the number of risk factors
that patients exhibited (Fig 2A). No significant difference was shown between groups 0 and 1
(Hazard ratio (HR) 1.73, P = 0.133), while groups 2 and 3 showed significant differences in
LRFFS compared with group 0. Patients in group 2 had a 3.2-fold higher risk of loco-regional
failure (P< 0.001, 95% CI 1.66–6.06) and patients in group 3 had a 6.5-fold higher risk
(P< 0.001, 95% CI 3.12–13.45) compared with those in group 0.
For OS, age (< 65 years), preoperative CA 19–9 ( 200 U/mL), postoperative CA 19–9
( 40 U/mL), N stage, AJCC stage, LVI, PNI, resection margin, and PNE were shown to be
prognostic factors with statistical significance in univariate analysis. In multivariate analysis, N
stage, PNI, and resection margin were independant prognostic factors associated with survival,
which were same as in LRFFS.
We investigated whether the same groups as defined by the number of risk factors used in
the LRFFS analysis would align with OS. Our data demonstrated that OS also appeared to
decrease sequentially in accordance with the higher number of risk factors (Fig 2B). Patients in
group 2 had a 3.3-fold higher risk for death (P = 0.001). Group 3, consisted of those who dis-
played all three risk factors, showed a 6-fold higher risk for death compared with group 0
(P< 0.001). However, patients in group 1 showed a 2-fold higher tendency for death
(P = 0.109).
Discussion
In this study, we analyzed the patterns of first failure in patients with resected pancreatic cancer
and investigated risk factors associated with LRFFS and OS. The purpose of this study was to
identify the subgroup that can benefit most from adjuvant RT. Among the patient demograph-
ics and clinical-pathological factors, preoperative CA 19–9 200 U/mL, N stage, and PNI
were significant prognostic factors associated with loco-regional failure. LRFFS and OS showed
Table 2. Patterns of failure.
Failure pattern No (%)
Local 47 (26.9)
Local only 27 (15.4)
Local & regional 2 (1.2)
Local & distant 16 (9.1)
Local & regional & distant 2 (1.2)
Regional 11 (6.3)
Regional only 3 (1.7)
Regional and distant 4 (0.6)
Distant 74 (42.4)
Distant only 52 (29.7)
doi:10.1371/journal.pone.0157196.t002
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Table 3. Prognostic factors for locoregional failure-free survival (LRFFS) and overall survival (OS).
LRFFS
UVA MVA
Characteristic HR 95% CI P HR 95% CI P
Age, years (< 65 vs.
65)
1.258 0.85–1.87 0.258
Sex (male vs.
female)
0.917 0.61–1.38 0.674
Diabetes mellitus
(no vs. yes)
1.014 0.67–1.53 0.947
ECOG performance
status (0 vs. 1)
1.58 1.06–2.35 0.023 1.315 0.86–2.01 0.206
Preop CA 19–9
(< 200 U/mL vs.
200 U/mL)
2.02 1.35–3.02 <0.001 1.738 1.04–2.92 0.037
Postop CA 19–9
(< 40 U/mL vs.
40 U/mL)
1.789 1.15–2.79 0.01 0.996 0.57–1.73 0.99
Tumor size (< 3cm
vs. 3cm)
0.756 0.50–1.14 0.185
T stage (T1-2 vs.
T3-4)
1.932 1.03–3.64 0.041 1.048 0.48–2.31 0.908
N stage (N0 vs. N1) 2.412 1.60–3.64 <0.001 1.661 1.03–2.69 0.04
Grade (WD-MD vs.
PD-UD)
0.953 0.48–1.90 0.891
LVI (no vs. yes) 1.643 1.09–2.48 0.018 1.134 0.72–1.79 0.589
PNI (no vs. yes) 1.975 1.28–3.06 0.002 1.813 1.09–3.01 0.021
Resection margin
(R0 vs. R1)
2.101 1.14–3.87 0.017 1.99 1.04–3.81 0.037
PNE (no vs. yes) 2.547 1.53–4.23 <0.001 1.57 0.88–2.82 0.13
Chemotherapy (no
vs. yes)
1.053 0.70–1.59 0.805
OS
UVA MVA
Characteristic HR 95% CI P HR 95% CI P
Age, years (< 65 vs.
65)
1.648 1.06–2.56 0.027 1.489 0.94–2.37 0.093
Sex (male vs.
female)
0.93 0.60–1.45 0.749
Diabetes mellitus
(no vs. yes)
0.947 0.60–1.50 0.816
ECOG performance
status (0 vs. 1)
1.373 0.89–2.13 0.157
Preop CA 19–9
(< 200 U/mL vs.
200 U/mL)
1.891 1.22–2.94 0.005 1.375 0.77–2.45 0.28
Postop CA 19–9
(< 40 U/mL vs.
40 U/mL)
2.034 1.26–3.29 0.004 1.289 0.72–2.33 0.398
Tumor size (< 3cm
vs. 3cm)
0.829 0.53–1.30 0.416
T stage (T1-2 vs.
T3-4)
1.658 0.87–3.16 0.125
N stage (N0 vs. N1) 2.439 1.55–3.83 <0.001 1.897 1.15–3.13 0.012
(Continued)
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significant differences between groups defined by the number of these risk factors they pos-
sessed. Patients with more than two risk factors had a 3.2- to 6.5-fold higher risk of loco-
regional failure, as well as a 3.3- to 6-fold higher risk of death with statistical significance. Thus,
we suggest that adjuvant radiotherapy could be beneficial for patients who have two risk factors
or more.
Our results are concordant with other prior data that demonstrated distant metastases as
the primary pattern of failure in this patient population. In our study, about 42% of patients
experienced distant metastasis and loco-regional failures occurred in 33.2% of patients. Simi-
larly, in the study from Johns Hopkins hospital, 68.9% of patients developed distant disease
and 31% of patients developed local failure as the first recurrence.[15] The experimental arm of
the CONKO-001 trial, which was assigned to receive gemcitabine after resection, experienced
distant metastasis rates of 56% and local failure rates of 34%.[16]
In the current practice of surgical resection followed by adjuvant chemotherapy, 60–70% of
patients still experienced recurrences after surgical resection.[15,16] To improve outcomes,
several studies have been performed to find the optimal adjuvant treatment. In the GITSG
trial, adjuvant CRT showed a significant benefit on survival; however, this study has been criti-
cized for the small number of patients evaluated (n = 43).[8,9] The EORTC 40891 phase III
trial was performed in Europe to investigate the effect of adjuvant RT with 5-FU. According to
this study, those who underwent adjuvant CRT had no significant improvement in survival
compared with those who received surgery alone.[10,11] In line with the GITSG and EORTC
trials, the ESPAC-1 trial was performed to demonstrate the effect of adjuvant CRT. Results
from the ESPAC-1 trial showed a deleterious effect of adjuvant CRT on survival (median 15.9
vs. 17.9 months, P = 0.05), whereas adjuvant chemotherapy had a significant survival benefit
(median 20.1 vs. 15.5 months, P = 0.009).[12,13] Based on the ESPAC-1 trial, current practice
was changed to omit adjuvant RT for patients with resected pancreatic cancer. However, the
ESPAC-1 trial has also been criticized due to its study design and quality control.[17,18] The
2×2 factorial design is inappropriate to make a decisive conclusion about the effect of adjuvant
CRT. Indeed, 33% of those assigned to receive chemotherapy did not complete their chemo-
therapy regimen. Moreover, 17% of the patients did not receive chemotherapy at all. With
respect to RT techniques, 40 Gy given in a split-course is no longer used in current practice.
Radiation field, dosimetry specifications, and overall quality assurance were not described.
To clarify the benefit of adjuvant CRT, several retrospective studies were performed.[19–23]
A retrospective study from the Mayo Clinic that included 472 patients investigated outcomes
after surgery alone versus surgery plus adjuvant CRT. OS was better in patients who received
adjuvant CRT (median OS, 25.2 vs. 19.2 months, P = 0.001).[19] Another large collaborative
study from the Johns Hopkins Hospital and Mayo Clinic [20] showed a survival benefit from
adjuvant 5-FU-based CRT compared with surgery alone (median 21.1 vs. 15.5 months,
Table 3. (Continued)
Grade (WD-MD vs.
PD-UD)
0.943 0.43–2.06 0.883
LVI (no vs. yes) 1.911 1.21–3.02 0.006 1.413 0.85–2.34 0.181
PNI (no vs. yes) 2.011 1.25–3.25 0.004 1.838 1.08–3.12 0.024
Resection margin
(R0 vs. R1)
2.305 1.18–4.51 0.015 2.113 1.02–4.36 0.043
PNE (no vs. yes) 2.165 1.20–3.92 0.011 1.13 0.57–2.26 0.729
Chemotherapy (no
vs. yes)
0.978 0.62–1.53 0.921
doi:10.1371/journal.pone.0157196.t003
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P< 0.001). In an analysis of the National Cancer Data Base (NCDB), 6165 patients with pT1-
3N0-1M0 pancreatic adenocarcinoma were categorized into two groups, namely adjuvant CRT
and adjuvant chemotherapy, and the outcome was assessed to provide a modern estimate of
comparative effectiveness. Adjuvant CRT was independently associated with improved OS
compared with adjuvant chemotherapy (median 22.3 vs. 20.0 months, P = 0.001).[23] The ben-
efit of adjuvant RT with modern techniques is still controversial and the subgroup that can
Fig 1. Prognostic factors associated with Loco-regional failure-free survival (LRFFS). Kaplan-Meier curves of Loco-regional failure-free survival
(LRFFS) stratified by (a) Initial CA 19–9, (b) N stage, (c) Perineural invasion (PNI) and (d) Resection margin.
doi:10.1371/journal.pone.0157196.g001
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benefit most from this approach is not well defined. A well-designed randomized controlled
study with modern techniques will be necessary to confirm the efficacy of adjuvant CRT in this
population. The RTOG 0848 phase II/III trial is now ongoing to compare gemcitabine together
with or without erlotinib hydrochloride and/or radiation therapy after surgery and the result is
pending.
In this study, initial CA 19–9 200 U/mL, N status, PNI, and resection margin were inde-
pendent risk factors correlated with LRFFS. Preoperative CA 19–9 level has been proven to be
an important predictor of recurrence and survival in patients treated with surgical resection
through previous studies.[24–26] In our previous study, CA 19–9 level was demonstrated to be
an important prognostic factor associated with survival in unresectable or borderline-resectable
pancreatic cancer patients treated with CRT.[27] Lymph node metastasis is also one of the
most significant predictive factors on survival.[13,26] Hsu et al.[20] analyzed pathologic N1
status as important factor associated with overall survival, and also demonstrated that resection
margin was a significant factor predicting survival.
We excluded patients who received neoadjuvant or adjuvant RT with an intention to elimi-
nate any possible effect of radiotherapy on loco-regional failure, which might be a major
Fig 2. The number of risk factors is associated with locoregional failure-free survival (LRFFS) and overall survival (OS). Kaplan-Meier curves of (a)
Locoregional failure-free survival (LRFFS) and (b) Overall survival (OS) according to the number of risk factors.
doi:10.1371/journal.pone.0157196.g002
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confounding factor. The patients who received adjuvant RT due to positive resection margin
were also excluded, which might have induced a selection bias. Fifteen patients with positive
resection margins included in this analysis were those who refused adjuvant RT despite their
positive resection margin status. Local recurrence was significantly higher in those patients, 9
out of 15 patients (60%) experienced local recurrence. In this study, resection margin status
was also revealed as an independent prognostic factor associated with LRFFS as well as OS.
This study is limited by the nature of its retrospective design. Data for the length of hospital
stay, postoperative recovery, and surgical complications were not available for some patients,
which might have been a significant influence in deciding their consequent adjuvant treatment.
The selection bias may occur in the process of excluding patients treated with adjuvant RT,
which was inevitable. The administration of adjuvant chemotherapy and the adjuvant chemo-
therapy regimens were not homogenous because they were administered according to the
clinician.
In conclusion, patients with more than two risk factors among initial CA 19–9 200 U/mL,
N1 stage, and PNI have a 3.2- to 6.5-fold higher risk of loco-regional failure, as well as a 3.3- to
6-fold higher risk of death. We suggest that adjuvant local radiotherapy is beneficial to improve
the survival outcome of patients with more than two risk factors. To clarify the effect of adju-
vant RT, future well-designed randomized controlled studies are needed.
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